|
[1]WHO.Hepatitis C[EB/OL][2015-04-28].http://www.who.int/mediacentre/factsheets/fs164/en/.
|
|
[2]WEBSTER DP,KLENERMAN P,DUSHEIKO GM.Hepatitis C[J].Lancet,2015,385(9973):1124-1135.
|
|
[3]SHAHEEN MA,IDRESS M.Evidence-based consensus on the diagnosis,prevention and management of hepatitis C virus disease[J].World J Hepatol,2015,7(3):616-627.
|
|
[4]COLPITTS CC,LUPBERGER J,DOERIG C,et al.Host cell kinases and the hepatitis C virus life cycle[J].Biochim Biophys Acta,2015,1854(10 Pt B):1657-1662.
|
|
[5]SHANG L,LIN K,YIN Z.Resistance mutations against HCV protease inhibitors and antiviral drug design[J].Curr Pharm Des,2014,20(5):694-703.
|
|
[6]BAKULIN I,PASECHNIKOV V,VARLAMICHEVA A,et al.NS3protease inhibitors for treatment of chronic hepatitis C:efficacy and safety[J].World J Hepatol,2014,6(5):326-339.
|
|
[7]HAYES CN,CHAYAMA K.Emerging treatments for chronic hepatitis C[J].J Formos Med Assoc,2015,114(3):204-215.
|
|
[8]KOHLER JJ,NETTLES JH,AMBLARD F,et al.Approaches to hepatitis C treatment and cure using NS5A inhibitors[J].Infect Drug Resist,2014,7:41-56.
|
|
[9] CORTEZ KJ,KOTTILIL S.Beyond interferon:rationale and prospects for newer treatment paradigms for chronic hepatitis C[J].Ther Adv Chronic Dis,2015,6(1):4-14.
|
|
[10]CHAYAMA K,TAKAHASHI S,TOYOTA J,et al.Dual therapy with the nonstructural protein 5A inhibitor,daclatasvir,and the nonstructural protein 3 protease inhibitor,asunaprevir,in hepatitis C virus genotype 1b-infected null responders[J].Hepatology,2012,55(3):742-748.
|
|
[11]LOK AS,GARDINER DF,LAWITZ E,et al.Preliminary study of two antiviral agents for hepatitis C genotype 1[J].N Engl J Med,2012,366(3):216-224.
|
|
[12]KUMADA H,SUZUKI Y,IKEDA K,et al.Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection[J].Hepatology,2014,59(6):2083-2091.
|
|
[13]LOK AS,GARDINER DF,HEZODE C,et al.Randomized trial of daclatasvir and asunaprevir with or without Peg IFN/RBV for hepatitis C virus genotype 1 null responders[J].J Hepatol,2014,60(3):490-499.
|
|
[14]MANNS M,POL S,JACOBSON IM,et al.All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:a multinational,phase 3,multicohort study[J].Lancet,2014,384(9954):1597-1605.
|
|
[15]SULKOWSKI MS,GARDINER DF,RODRIGUEZ-TORRES M,et al.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection[J].N Engl J Med,2014,370(3):211-221.
|
|
[16]AFDHAL N,ZEUZEM S,KWO P,et al.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection[J].N Engl J Med,2014,370(20):1889-1898.
|
|
[17]AFDHAL N,REDDY KR,NELSON DR,et al.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection[J].N Engl J Med,2014,370(16):1483-1493.
|
|
[18]KOWDLEY KV,GORDON SC,REDDY KR,et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis[J].N Engl J Med,2014,370(20):1879-1888.
|
|
[19]LAWITZ E,SULKOWSKI MS,GHALIB R,et al.Simeprevir plus sofosbuvir,with or without ribavirin,to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study[J].Lancet,2014,384(9956):1756-1765.
|
|
[20]GANE EJ,STEDMAN CA,HYLAND RH,et al.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C[J].N Engl J Med,2013,368(1):34-44.
|
|
[21]OSINUSI A,MEISSNER EG,LEE YJ,et al.Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics:a randomized clinical trial[J].JAMA,2013,310(8):804-811.
|
|
[22]JACOBSON IM,GORDON SC,KOWDLEY KV,et al.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options[J].N Engl J Med,2013,368(20):1867-1877.
|
|
[23]ZEUZEM S,DUSHEIKO GM,SALUPERE R,et al.Sofosbuvir and ribavirin in HCV genotypes 2 and 3[J].N Engl J Med,2014,370(21):1993-2001.
|
|
[24]CORTEZ KJ,KOTTILIL S.Beyond interferon:rationale and prospects for newer treatment paradigms for chronic hepatitis C[J].Ther Adv Chronic Dis,2015,6(1):4-14.
|
|
[25]EVERSON GT,SIMS KD,RODRIGUEZ-TORRES M,et al.Efficacy of an interferon-and ribavirin-free regimen of daclatasvir,asunaprevir,and BMS-791325 in treatment-naive patients with HCV genotype 1 infection[J].Gastroenterology,2014,146(2):420-429.
|
|
[26]POORDAD F,LAWITZ E,KOWDLEY KV,et al.Exploratory study of oral combination antiviral therapy for hepatitis C[J].N Engl J Med,2013,368(1):45-53.
|
|
[27]LAWITZ E,POORDAD F,KOWDLEY KV,et al.A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals(ABT-450/r,ABT-072)and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1[J].J Hepatol,2013,59(1):18-23.
|
|
[28]FELD JJ,KOWDLEY KV,COAKLEY E,et al.Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin[J].N Engl J Med,2014,370(17):1594-1603.
|
|
[29]FERENCI P,BERNSTEIN D,LALEZARI J,et al.ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV[J].N Engl J Med,2014,370(21):1983-1992.
|
|
[30]ZEUZEM S,JACOBSON IM,BAYKAL T,et al.Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin[J].N Engl J Med,2014,370(17):1604-1614.
|
|
[31]POORDAD F,HEZODE C,TRINH R,et al.ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis[J].N Engl J Med,2014,370(21):1973-1982.
|
DownLoad: